<SEC-DOCUMENT>0001193125-25-016277.txt : 20250130
<SEC-HEADER>0001193125-25-016277.hdr.sgml : 20250130
<ACCEPTANCE-DATETIME>20250130080520
ACCESSION NUMBER:		0001193125-25-016277
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250130
DATE AS OF CHANGE:		20250130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		25571227

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d907461d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>8,850,000 American Depositary Shares representing 885,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g907461g0130000144488.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on January&nbsp;30, 2025 (the &#147;January 30, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the January&nbsp;30, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and
supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in
conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On January&nbsp;29, 2025, the last reported sale
price of the ADSs on Nasdaq was $1.38 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is January&nbsp;30, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of January, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2025, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled &#147;Kazia Therapeutics
announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the respective quotes of
Dr.&nbsp;John Friend, Chief Executive Officer of the Company, and Sudha Rao, Professor at QIMR Berghofer, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated January&nbsp;30, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited </B>(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 30&nbsp;January 2025</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>combination with immunotherapy in women with advanced breast cancer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney; 30&nbsp;January 2025: Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory
approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly
aggressive and treatment-resistant type of breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ABC-Pax (Advanced Breast Cancer &#150; Paxalisib) study is the first known trial conducted
to assess the safety and efficacy of paxalisib in combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) or LYNPARZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (olaparib) in women with
triple negative breast cancer. ABC-Pax is a multi-centre, open-label phase 1b study that will enroll 24 patients from top cancer centres in Queensland, Australia and patients will receive the combination therapy for up to 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ABC-Pax study stems from pivotal research led by QIMR Berghofer scientists in collaboration with Kazia Therapeutics, which combined its drug candidate,
paxalisib, with immunotherapy in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. The team discovered that this combination approach triggers a novel molecular program by epigenetic <FONT STYLE="white-space:nowrap">re-programming</FONT>
of dormant cancer cells, making them visible to the immune system, while also reinvigorating the immune cells to fight the tumour cells. These new preclinical data were presented at San Antonio Breast Cancer Symposium on December&nbsp;12, 2024, and
highlight the potential therapeutic synergies between paxalisib and checkpoint inhibitor pembrolizumab (KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), as well as between paxalisib and poly
<FONT STYLE="white-space:nowrap">(ADP-ribose)</FONT> polymerase inhibitor olaparib (LYNPARZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), when used in combination in a preclinical model of immunotherapy-resistant triple negative
breast cancer. The clinical trial is open for enrollment at the Royal Brisbane and Women&#146;s Hospital and plans to expand to other sites in Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics CEO, Dr John Friend, said the novel combination treatment may have the potential to transform the treatment of triple-negative breast
cancer and other aggressive tumour types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The novelty of the science that Professor Rao has proposed with this dual combination of paxalisib and
immunotherapy could advance the treatment of women with aggressive breast cancer, and we are excited to support this unique clinical study,&#148; Dr John Friend, CEO Kazia Therapeutics said. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QIMR Berghofer&#146;s Professor Sudha Rao said, &#147;There is no cure for triple negative breast cancer and the life expectancy for these women is tragically
short. We want to identify treatments to extend the duration and quality of life of these patients. The hope is to prolong patient survival through the new combined therapy, which targets the dormant cancer cells that drive the spread and recurrence
of the disease and rejuvenates the immune system to more effectively fight the cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ABC-Pax trial will also evaluate a <FONT
STYLE="white-space:nowrap">non-invasive</FONT> liquid biopsy digital pathology platform developed by Professor Rao and her team, which can monitor the behaviour of cancer cells and immune cells in real time from a blood sample. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;By regularly analysing blood samples from trial participants using our liquid biopsy digital pathology platform, we can track the effectiveness of the
treatment in real time. We believe this approach represents a major advance in precision medicine by offering a faster and more accurate way to monitor patient progress,&#148; Professor Rao said. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor and Media Contacts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Star </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director; LifeSci Advisors LLC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astarr@lifesciadvisors.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ:&nbsp;KZIA) is an oncology-focused drug development company, based in&nbsp;Sydney, Australia. Our lead program is
paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical
trials in this disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a
standard approval. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug
Designation for glioblastoma by the FDA in&nbsp;February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in&nbsp;August 2020. Paxalisib was also granted FTD in&nbsp;July 2023&nbsp;for the treatment of solid tumour brain metastases
harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in&nbsp;August 2020, and for
atypical teratoid / rhabdoid tumours in&nbsp;June 2022&nbsp;and&nbsp;July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in&nbsp;April 2021. Preclinical data has shown
EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium
in&nbsp;September 2024. For more information, please visit&nbsp;www.kaziatherapeutics.com&nbsp;or follow us on X @KaziaTx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials,
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the ABC-Pax study and the potential results of combination studies of paxalisib, the potential benefits of paxalisib as an investigational PI3K/mTOR
inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia&#146;s current expectations and projections about future events and
future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with
clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed
on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g907461g0130000144488.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g907461g0130000144488.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W;: !@=*I
M:IJ/]F6#S^7N.0%!]3ZT_4Y9HM,GD@ ,BK\N/UK&T":YU-+B'4%:6' QO'>M
M*=-<O,]ET.6K6:G[..[6CZ(6'4+G6M&NO)C\NY3"_*>#]#VXIOAZRU&WMKI9
M=T:NN(U8\[N>:M76HZ3X?*6[D1B0Y"J/PR:I>(?%+Z1=VZ00B5)(]^X]QZ"E
M+$1BG&*TN:4L#4J.,Y7YM?),9H-CJ=MJ$LEPK+'M)DR<ASZBK6G^(FNM6^RM
M %1B50@\\>M6[OQ'I]D;>.[<H\RA@N,[0?6IFL+6".6\M84^T,A96 ZYJU6C
M-OF6K_ R>&J4(IINVKU_0T_J*?VKD_#E[J%S?RQW)=HPN3O['VKJ_6LYQY'8
MUHU55AS)6'44T=*\<7QYKY\?_P!EFX06G]H_9PNP9V;\?RI)-HU;L['LU%<5
MXZ\9)X7T_P JW*OJ,H_=J>=@_O&J7P\U3Q+KL4NHZK.IL2NV)=@!<_WOI1RN
MUQ<RO8]"HIJYVC/I1SNQ2*'4E>:'X@'_ (68-,\P?V7_ ,>V?^FO][\^*]+'
M2FTT)-,7M24=J\Y^(7B'7]$OK*/1U<I)&Q?;%NYS^E)*[!NQZ-1FO )OB+XP
MML>?(8MWW?,AVYKT#X<:QKFOVUU?ZK,K6^X1P (!EA]X_P A5N#2N)23._HQ
M31Z5Y'XQ\;Z[H_C233;*=4MU\K"E ?O8SS4Q38W*QZ_144#%H$8]2H)J6D,*
M0UA^*=:C\/Z!=:@S .B$1 ]W/2L?X>^)Y/$6@9NY-]];-LF_V@>0?R_E3Y7:
MXKJ]CM**%.112&<?J>JZC!K/DQ(?+# *N.&%:FM:F-'TIKM8=S9 "CID^M4;
M'7A>ZPL#VZA6)"-CD8IGBC74TQX[-[59EF7<P;ICI^=:57RQ2:MH88*'/5<K
M\R;V]"M!96OC*RCO[E'BFB)B.T\,,UTS:=:21Q)) CB$ )N&<4W3D@73X3;Q
M".-E#!0.F:XW4-:O)[Z39*R(K$*HJ</0=6]F:XS&^QMO:[LCH=6\-6>KW23S
M$AD&TX[@53TSQ,9]=_LK[,5B4F-#W&..:T_#E_+?Z=NF.9(SM)]:Q=<UJWT3
M74\JQ1II%#/)CDYK&<'3D_4Z*57V\$FKZ:>1H>(+NZL1"+0%!)G<ZK6KI4\U
MQIL$MRNV5EY%0ZI?BSTL77E!P<85ATS4>A:FVJ6S/)&%:-L<=#70TY0VV/.B
ME"ORN6ZV-H=J^:-1O/[.^(-Y?;=_V?47E"^N'S7TN*^<#&D_Q1>&10T;ZLRL
MI[@R8HI]3>?0LZ%9S^/O&[-J%P K$RR#/.T?PK7OUK;0VEK';VZ+'%&H5%4<
M "O!?%&AWG@/Q2E[8,R6[/YD$@Z#G[IKV/PIXDMO$VCQW<)"R@8FCSRK435U
MIL$=&= *YWQGKJ^'O#5W>@CSROEPC/5STKH,UX9\5=>.I:_%I-NVZ&S^^%[R
M'_ <5$%=E2=D<5]AO_[-_MK:YA^T"/S?]OKFOH7P7KJ^(O#5K=EOWRCRIA_M
MKU_/K7BP\27O_"(_\(Y_9:_9^OF!#NW9SGZUM?"O73INOR:5<,4AO1\H/\,@
MZ?F.*VFKHSB[,]T'2HG5"2753@9R1VJ0=*XOXB^(O["\-R)$^+N[S%$ >0/X
MC^58Q5W8U;TN>8^,=2D\7^-EL;  Q)(+:W"C@G/+?S_*O<-$TN'1M&M=/A V
M0H%SZGN?SKQCX:-H]CJL^JZK=QQ/#\L"N>YZM7M&EZUI^KQNVGW23K'@-M[5
M=2ZT(A9ZFD:^?/B-_P E*F^L/]*^@NU?/OQ&_P"2E3_6'^E*EN%38]_M_P#C
MVB_W!_*I"><5';_\>T7^X/Y51UO5(M%T>ZU&<X2",M]3V%1U+Z'DWQ8UQK_5
M[;0;9BRP$-(H_BD/ _+^M9/@V_N/!_CG[%?9BCE;R)U/0$_=/YG-<]:ZK=MX
MB_MJ2W^U3B8S,I&06ZC-3>(]9N_$&I?VG<6?V>0( S(I&<=#]:Z+65C!N[N?
M3:?=HKDO FO/K_AB"4LK7,'[F;<><CH?Q%%8<IMS$TE[IFF:L5\D"8GYG'\.
M:G\326=OI?VRZMA/Y9&P$>M+J>CV37+:E/D!!N<#OBI+6_L->AEM@NY5 RK#
M\JTJQYX)QWZF.$G[*K:>U]/0/#VIKJ^EB=8O**G84],56OO#$5U=M,DOEESD
MC%96OR:CH\EM;:1 4M]NX[%SELU=U;Q.^CFT2:V+2R1!Y!_=]:YZ59TVU?5'
M;B,-"K9VNG=I&[I]C%IUJMO%T'))[FN;AUNSU7Q-]AGLU8HQ6.1ASD4WQ!J>
MKK=VC:;&_D2('!"YW$]C6]!I]G;_ /$PD@1+C8'D8#H<<TI2E4?S+A"%"G>7
M5:>1%K-_:V42Q7,?F"7HF/2K>D_96L4>T0)$W.!6.\VG>))Q"-ZR19VMZBN@
MM+6.SMXX(AA%&*ZII1@H]>IYE.\ZKFG=%D=J\Y'PS \6?VU]N_Y>S<^7M_VM
MV*]&%4OMT)OC:Y;S?3'&/6LHMZV.B5M+E/Q!H-IXCTJ6PNE&&Y1\<HWK7.>$
MO ,_A;53<Q:FTD+*5DBQPWI78"]MVC5@_P K/Y8/O_D4"_@-P;<%MX(!XZ4U
MS6%S1Z,L,I,;;3AB.#Z5Y]I'PSBL_$2ZM>WANF#M(8V'5CZUVZZC;F?R-YW[
M]@XXS4WVB(S_ &<L/,*[MO?%"NA\T7K<;_9MEC/V2'C_ &!7":K\,HKWQ&VK
M6-Y]D8NLFQ1PK#N*[@ZA;BY-N7/F9"].,TJ7\$EPT*[F<-M/' (H7,)RB^I9
M0$(H8Y..3ZFN(\7> 9/%6JQW3Z@T4<481(\<#GFNQ%[$RQD/D2.44^XS_A3(
M]1ADN&@4MO7[V1TH5UJAMQZGE_\ PIG/75/_ !VNO\%^#?\ A$H;M/M)G^T,
M#TQC%= VH0);I.7RC\+CJ30^HP) LQ8[7.T#')/TIN4GN*\$7:\_\1_#?^W_
M !*VK?;?+#;/DQ_=KOHV$B*X[C-/P*A-HNR8R)=D2IUV@#-<WXP\-3>*=,CL
M4NS;QB3>^!][CC]:ZBFTT[:@U?0Y;PMX-L?#NE&U94N9'<N\KKUJ]K/ARQU?
M2;FQ:".,3)@.J %3ZUMX%+BCF=[ARJUCS+2_ -_X=21+36F19B"P"]Q_^NBO
M3=H]**.87*4[BVCNK9X)/N.,'%89MHO#-E-=1%II& 4;N*Z)?]73)((IX6CE
M0,K=0:<)M:=#*I23>GQ=S(T?5QJ-K)+<*L9B;YF[5,T.E:V1,Z13F$]3V^M-
MO;"W31;B"%!$A7^&LCPM;*\-ZVXC<#'@=AS6OL82@Y^9A[>K1J1IMWWU.AM[
M^SN':*&5&,0Y1?;TK#L]>DU#4'LI(!Y4A9>.HJMX<LUBU:4AV/EI@>]=1#8V
MT,S3I$HD;JV*'"--M$PE4KVUM:]RGIF@V^FW#3QLS,1@ ]A6T,4P >E.[5E*
M3D[L[*=.,(VB.JB;9CJAN/X?*"?CG-7J;4IV+<>8PUTJ1$B;<=RW&\C=QMR?
M\14T-E<1ZG++M/ENP.X/[>E:V!1QZ57.S/V,4[F+%IDRWHE+9C\YG*D\#/0C
MWIK6%U]O^U[E+B3Y5']SIUK<HV@T<[N'L8I:&7'IF;Z:XE9MID#HN>.!UJ.V
ML[B"]F8@F.20N&W\8..U;%&!Z4<[!T8M&+%87(GB1MODQ3-(K@]<YX_6KD=L
MZW]S,2-DB*%Y],Y_G5[ ]*./2DY@J43%6PN([6S**K3VW\!. <_UJ:YBN9K)
M08E\T'(VOC9Z'-:E%/F&Z2L06BRI:1K.0TH4!B.A-6:3[HXI:DM*RL+1244#
,%HI** %HI** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
